Completed Studies

Previous Achievements

  1. A randomised, multicentre, open-label,  phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErB2 positive primary breast cancer.
  2. A multicentre phase III randomized trial of adjuvant therapy of patients with HER2-positive node-postive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab.
  3. An international multicentre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.  
  4. HERA: A randomised three-arm multicentre comparison of 1 year and 2 years of Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy.